New Platform Supports Integrated Drug Discovery Solutions

A comprehensive platform designed to support every stage of cancer drug discovery projects, comprising target research, hit identification, hit-to-lead, and lead optimisation - The Reaction Oncology Platform - has been announced by a leading small molecule provider, Reaction Biology.

The Reaction Oncology Platform is based on a network of strategic partners, including oncology and biophysics by the US and Germany-based Reaction Biology, medicinal chemistry, and ADME-tox by Netherlands-based Symeres, and advanced cardiac safety/ion channel drug discovery by US/China-based PharmaCore Labs.

“Communication and problem-solving are our strengths enabling us to tackle challenging projects with close collaboration with the client and among the various teams,” said Kelvin Lam, the company's Vice President of Strategic Business Development. “True to our reputation as a service-oriented company, we facilitate direct contact between the client and our team of multidisciplinary scientists.”

Haiching Ma, Reaction Biology’s CSO, stated: “The value of the Reaction Oncology Platform lies in the expertise of our partner network. No company can be the best in all disciplines; therefore, we choose the best partners to create a premier platform for oncology drug discovery. Our joint capabilities enable clients to create new chemical entities against challenging targets to fight cancer.”

More information online